Jasper Therapeutics Inc. (JSPR) Stock Price, Quote & News

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic sp...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 549 1400

Website: jaspertx.com

Address:

2200 Bridge Pkwy, Suite 102, Redwood City, United States

MulaBagz Apr. 8 at 5:46 PM

$JSPR let’s see a gap

0 · Reply

Bullshyte Apr. 8 at 4:53 PM

$JSPR I believed that this has hopefully bottomed...

0 · Reply

Bio_Be_Dirty Apr. 8 at 5:53 AM

$JSPR don’t be a jasper

0 · Reply

SQUEAKSBANDIT Apr. 7 at 5:26 PM

$JSPR is there a last minute scenario where they partner ? would someone be willing to pay all of the development costs going fwd? and for how big a piece of the pie?

0 · Reply

KOWALSK1 Apr. 7 at 8:54 AM

$JSPR JASPER THERAPEUTIC ✅️ BUY ZONE 0.68 0.65 ✋️ RISK BELOW 0.60 🎯 PT. 0.71 0.89 0.97 1.13 1.20 1.24 + UP Follow for more

0 · Reply

LabPsycho Apr. 6 at 6:57 PM

$JSPR @SQUEAKSBANDIT Good point. I would like to see it go off a cliff (moreso than it already has) on lower volume - that might be a signal and entry point to try to play a bounce.

1 · Reply

SauceBoass Apr. 5 at 10:41 PM

$JSPR Dependence on a Single Product or Pipeline..

0 · Reply

AshleySchaeffer_BMW Apr. 5 at 5:02 PM

$JSPR more pain coming here, only 26 cents cash per share on hand, and will be running out of money soon, offering coming most likely in the next few weeks....

0 · Reply

SQUEAKSBANDIT Apr. 3 at 6:34 PM

$JSPR is it possible they're preparing an offering shares + 100% warrant coverage and those who anticipate buying this deal are shorting as much as they can? and if so where does that leave the stock <.50?

1 · Reply

UnoffensiveName Apr. 2 at 10:11 PM

$JSPR No upcoming catalyst except a likely Rivers split Looking grim

1 · Reply

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Feb 24, 2026, 4:30 PM EST - 6 weeks ago

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

Jan 8, 2026, 7:00 AM EST - 3 months ago

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Jan 7, 2026, 4:30 PM EST - 3 months ago

Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

Dec 2, 2025, 7:00 AM EST - 4 months ago

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Dec 1, 2025, 4:30 PM EST - 4 months ago

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Nov 22, 2025, 11:49 PM EST - 4 months ago

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

DRVN

Nov 17, 2025, 12:13 PM EST - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 10, 2025, 6:53 PM EST - 5 months ago

JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 10, 2025, 8:00 AM EST - 5 months ago

Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 7, 2025, 9:52 AM EST - 5 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 4, 2025, 8:00 AM EST - 5 months ago

Jasper Therapeutics to Present at Upcoming Investor Conferences

Oct 10, 2025, 8:05 PM EDT - 6 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Sep 22, 2025, 1:05 PM EDT - 7 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)

Sep 19, 2025, 12:07 AM EDT - 7 months ago

Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Sep 18, 2025, 4:08 PM EDT - 7 months ago

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Aug 13, 2025, 4:05 PM EDT - 8 months ago

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 11, 2025, 12:18 PM EDT - 9 months ago

JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Jul 9, 2025, 8:00 AM EDT - 9 months ago

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

Jul 7, 2025, 1:25 PM EDT - 9 months ago

Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem

Jul 7, 2025, 7:30 AM EDT - 9 months ago

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

Jun 14, 2025, 10:00 AM EDT - 10 months ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jun 3, 2025, 8:00 AM EDT - 11 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

May 12, 2025, 4:05 PM EDT - 11 months ago

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 1, 2025, 12:45 PM EST - 1 year ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 28, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Feb 25, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Feb 10, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 4, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jan 8, 2025, 7:00 AM EST - 1 year ago

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 6, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Dec 2, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Nov 13, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 14, 2024, 9:22 AM EDT - 1 year ago

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Sep 10, 2024, 7:30 AM EDT - 1 year ago

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

Sep 4, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

MulaBagz Apr. 8 at 5:46 PM

$JSPR let’s see a gap

0 · Reply

Bullshyte Apr. 8 at 4:53 PM

$JSPR I believed that this has hopefully bottomed...

0 · Reply

Bio_Be_Dirty Apr. 8 at 5:53 AM

$JSPR don’t be a jasper

0 · Reply

SQUEAKSBANDIT Apr. 7 at 5:26 PM

$JSPR is there a last minute scenario where they partner ? would someone be willing to pay all of the development costs going fwd? and for how big a piece of the pie?

0 · Reply

KOWALSK1 Apr. 7 at 8:54 AM

$JSPR JASPER THERAPEUTIC ✅️ BUY ZONE 0.68 0.65 ✋️ RISK BELOW 0.60 🎯 PT. 0.71 0.89 0.97 1.13 1.20 1.24 + UP Follow for more

0 · Reply

LabPsycho Apr. 6 at 6:57 PM

$JSPR @SQUEAKSBANDIT Good point. I would like to see it go off a cliff (moreso than it already has) on lower volume - that might be a signal and entry point to try to play a bounce.

1 · Reply

SauceBoass Apr. 5 at 10:41 PM

$JSPR Dependence on a Single Product or Pipeline..

0 · Reply

AshleySchaeffer_BMW Apr. 5 at 5:02 PM

$JSPR more pain coming here, only 26 cents cash per share on hand, and will be running out of money soon, offering coming most likely in the next few weeks....

0 · Reply

SQUEAKSBANDIT Apr. 3 at 6:34 PM

1 · Reply

UnoffensiveName Apr. 2 at 10:11 PM

$JSPR No upcoming catalyst except a likely Rivers split Looking grim

1 · Reply

LabPsycho Apr. 2 at 2:04 PM

$JSPR @Assel17 I am surprised every day since earnings breached below $1, down 5-7 cents a day is painful to watch. It almost seems as if they will be closing their doors? Maybe no dead cat bounce for this on?

1 · Reply

Assel17 Apr. 1 at 7:48 PM

$JSPR This is classic “dead cat bounce candidate” territory.

1 · Reply

Gmblr777 Mar. 31 at 3:33 PM

$JSPR no bottom

1 · Reply

Drugtrade Mar. 31 at 3:19 PM

$JSPR man i wish i shorted this.. going to zero

0 · Reply

focafoca99 Mar. 31 at 2:07 AM

$JSPR is using the year-end update to keep briquilimab in focus, with chronic urticaria data in hand and Phase 2b/3 enrollment still targeted for 2H 2026 if capital is there.

0 · Reply

Mapago Mar. 30 at 8:32 PM

$JSPR Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

0 · Reply

Gmblr777 Mar. 30 at 7:52 PM

$JSPR looks like no chance to hold 0.90$

0 · Reply

JValis Mar. 30 at 7:14 PM

$JSPR 😐

0 · Reply

Gmblr777 Mar. 30 at 7:03 PM

$JSPR not looking good…

0 · Reply

AshleySchaeffer_BMW Mar. 30 at 6:25 PM

$JSPR will average down in the 70s, think the current macro takes us there

0 · Reply

AshleySchaeffer_BMW Mar. 30 at 6:24 PM

$JSPR hate to say it but called it...

0 · Reply

SQUEAKSBANDIT Mar. 30 at 5:49 PM

$JSPR am i reading this right they could be out of cash in 3 months ?

1 · Reply

Market Cap	19.16M
Revenue (ttm)	0.00
Net Income (ttm)	-75.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	503,575
Avg Vol	468,392
Day's Range	N/A - N/A
Shares Out	28.00M
Stochastic %K	8%
Beta	3.20
Analysts	Sell
Price Target	$7.70